Clinical Study on the Treatment of Posterior Circulation Ischemic Vertigo with Xuesaitong Injection Combined with Cerebroprotein Hydrolysate for Injection (Ⅲ)
Objective To explore the therapeutic effect of Xuesaitong for injection combined with cerebroprotein hydro-lysate for injection ( Ⅲ ) on patients with posterior circulation ischemic vertigo.Methods 86 patients with posterior circulation ischemic vertigo were randomly divided into a control group ( n=43,treated with cerebroprotein hydrolysate for injection ( Ⅲ ) ) and an observation group ( n=43,treated with Xuesaitong injection in addition to the control group ) using the envelope drawing meth-od.The efficacy,blood rheology,cerebral blood flow,serum cytokines,and adverse drug reactions were compared between the two groups.Results The therapeutic effect of the observation group was better than that of the control group ( 93.02％ vs.72.09％ ) ( P<0.05 ) .After treatment,the cerebral blood flow velocity of the vertebrobasilar artery,left and right vertebral arteries,and serum calcitonin gene-related peptide levels were higher than those before treatment ( P<0.05 ),and the plasma viscosity,whole blood viscosity,platelet adhesion rate,and endothelin-1 levels were lower than those before treatment ( P<0.05 ) .The im-provement in the observation group was better than that in the control group ( P<0.05 ) .There was no significant difference in the incidence of adverse reactions between the two groups ( P>0.05 ) .Conclusion The combination of Xuesaitong injection and cerebroprotein hydrolysate for injection ( Ⅲ ) has a better therapeutic effect on patients with posterior circulation ischemic vertigo,which may be related to promoting blood flow recovery and improving vascular endothelial injury.
万方数据
维普
